Edwin H. Yau

Oncology

665 Elm St
Buffalo, NY 14203

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 25 publications

Mesothelioma: Pleural, Version 3.2026, NCCN Clinical Practice Guidelines In Oncology.

Mesothelioma: Pleural, Version 3.2026, NCCN Clinical Practice Guidelines In Oncology.

Journal: Journal of the National Comprehensive Cancer Network : JNCCN

Published: August 17, 2026

Targeting Distinct Cell Cycle Nodes Overcomes KRAS/RAS Inhibitor Resistance.

Targeting Distinct Cell Cycle Nodes Overcomes KRAS/RAS Inhibitor Resistance.

Journal: bioRxiv : the preprint server for biology

Published: April 10, 2026

Non-Small Cell Lung Cancer, Version 4.2026, NCCN Clinical Practice Guidelines In Oncology.

Non-Small Cell Lung Cancer, Version 4.2026, NCCN Clinical Practice Guidelines In Oncology.

Journal: Journal of the National Comprehensive Cancer Network : JNCCN

Published: April 09, 2026

NCCN Guidelines® Insights: Non-Small Cell Lung Cancer, Version 7.2025.

NCCN Guidelines® Insights: Non-Small Cell Lung Cancer, Version 7.2025.

Journal: Journal of the National Comprehensive Cancer Network : JNCCN

Published: September 10, 2025

Tumor-Derived Complement C3 Overexpression in STK11-Mutant Lung Adenocarcinoma Drives Tumor Growth and Immune Checkpoint Inhibitor Resistance.

Tumor-Derived Complement C3 Overexpression in STK11-Mutant Lung Adenocarcinoma Drives Tumor Growth and Immune Checkpoint Inhibitor Resistance.

Journal: Cancer immunology research

Published: April 23, 2025

Non-Small Cell Lung Cancer, Version 4.2024, NCCN Clinical Practice Guidelines in Oncology

Non-Small Cell Lung Cancer, Version 4.2024, NCCN Clinical Practice Guidelines in Oncology

Journal: Journal of the National Comprehensive Cancer Network : JNCCN

Published: May 16, 2024

NCCN Guidelines® Insights: Mesothelioma: Pleural, Version 1.2024.

NCCN Guidelines® Insights: Mesothelioma: Pleural, Version 1.2024.

Journal: Journal of the National Comprehensive Cancer Network : JNCCN

Published: March 19, 2024

Patients' Preferences for Adjuvant Osimertinib in Non-Small-Cell Lung Cancer After Complete Surgical Resection: What Makes It Worth It to Patients?

Patients' Preferences for Adjuvant Osimertinib in Non-Small-Cell Lung Cancer After Complete Surgical Resection: What Makes It Worth It to Patients?

Journal: Clinical lung cancer

Published: January 28, 2024

Mesothelioma: Peritoneal, Version 2.2023, NCCN Clinical Practice Guidelines in Oncology.

Mesothelioma: Peritoneal, Version 2.2023, NCCN Clinical Practice Guidelines in Oncology.

Journal: Journal of the National Comprehensive Cancer Network : JNCCN

Published: September 06, 2023

Neoadjuvant Durvalumab Alone or Combined with Novel Immuno-Oncology Agents in Resectable Lung Cancer: The Phase II NeoCOAST Platform Trial.

Neoadjuvant Durvalumab Alone or Combined with Novel Immuno-Oncology Agents in Resectable Lung Cancer: The Phase II NeoCOAST Platform Trial.

Journal: Cancer discovery

Published: April 21, 2023

NCCN Guidelines® Insights: Non-Small Cell Lung Cancer, Version 2.2023.

NCCN Guidelines® Insights: Non-Small Cell Lung Cancer, Version 2.2023.

Journal: Journal of the National Comprehensive Cancer Network : JNCCN

Published: April 04, 2023

Adagrasib in Non-Small-Cell Lung Cancer Harboring a KRASG12C Mutation.

Adagrasib in Non-Small-Cell Lung Cancer Harboring a KRASG12C Mutation.

Journal: The New England journal of medicine

Published: June 03, 2022

Showing 1-12 of 25

Last Updated: 09/26/2026